All In Biotech

Drug Trial Radar · NCT02814916

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections

Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 199 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

199

Actual

Start

Mar 30, 2017

Primary completion

Jan 1, 2024

Study completion Jan 1, 2024

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jun 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by susceptible Gram-positive organisms, including methicillin-resistant strains of Staphylococcus aureus.

Conditions

  • Methicillin-Resistant Staphylococcus Aureus
  • Bacterial Infections
  • Staphylococcal Skin Infections

Interventions

  • DalbavancinDrug

    Dalbavancin was administered intravenously over 30 (± 5) minutes.

  • VancomycinDrug

    Vancomycin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.

  • OxacillinDrug

    Oxacillin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.

  • FlucloxacillinDrug

    Flucloxacillin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.

  • CefadroxilDrug

    Cefadroxil was administered orally every 12 hours.

  • ClindamycinDrug

    Clindamycin was administered orally every 8 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Shift From Baseline in Distortion Product Otoacoustic Emission at TOC VisitTime frame: Baseline, Day 28 (± 2 days)
  2. Shift From Baseline in Auditory Brainstem Response Test at TOC VisitTime frame: Baseline, Day 28 (± 2 days)
  3. Shift From Baseline in Acoustic Immittance Test at TOC VisitTime frame: Baseline, Day 28 (± 2 days)
  4. Shift From Baseline in Behavioral Audiometric Valuation at TOC VisitTime frame: Baseline, Day 28 (± 2 days)
  5. Shift From Baseline in Clostridium Difficile (CD) and Vancomycin-resistant Enterococci (VRE) at TOC VisitTime frame: Baseline, Day 28 (± 2 days)

Locations

84 sites in 20 countries. Site status is shown where the registry gives one.

  • University of South Alabama /ID# 237446

    Mobile, Alabama

  • Valleywise Health Medical Center /ID# 234343

    Phoenix, Arizona

  • Southbay Pharma Research /ID# 235700

    La Palma, California

  • University of California, Los Angeles /ID# 237533

    Los Angeles, California

  • Duplicate_Children's Hospital Colorado /ID# 237622

    Aurora, Colorado

  • Global Research Holdings LLC /ID# 235747

    Panama City, Florida

  • Tampa General Hospital /ID# 237061

    Tampa, Florida

  • Children's Healthcare of Atlanta - Ferry Rd /ID# 237003

    Atlanta, Georgia

  • University of Maryland Medical Center /ID# 234353

    Baltimore, Maryland

  • Duplicate_Children's Mercy Hospital and Clinics /ID# 237800

    Kansas City, Missouri

  • Robert Wood Johnson Univ Hosp /ID# 237862

    New Brunswick, New Jersey

  • NYU School of Medicine /ID# 236783

    New York, New York

  • SUNY Upstate Medical University /ID# 236831

    Syracuse, New York

  • Duke University Medical Center /ID# 234315

    Durham, North Carolina

  • Cleveland Clinic Main Campus /ID# 237564

    Cleveland, Ohio

  • Hospital de Ninos Dr. Orlando Alassia /ID# 235562

    Santa Fe, Argentina

  • Grodno Regional Infectious Disease Hospital /ID# 235661

    Grodno, Belarus

  • Mogilev Regional Children's Hospital /ID# 235657

    Mogilev, Belarus

  • Vitebsk Regional Clinical Center for Children /ID# 235659

    Vitebsk, Belarus

  • Duplicate_Hospital Pequeno Princípe /ID# 235629

    Curitiba, Paraná, Brazil

  • Duplicate_Irmandade Santa Casa de Misericórdia de Porto Alegre /ID# 235627

    Porto Alegre, Rio Grande do Sul, Brazil

  • University Multiprofile Hospital for Active Treatment Deva Maria EOOD Burgas /ID# 235965

    Bulgas, Bulgaria

  • MHAT (Multiprofile Hospital for Active Treatment) /ID# 235539

    Kozloduy, Bulgaria

  • UMHAT Dr Georgi Stranski EAD /ID# 237829

    Pleven, Bulgaria

  • UMHAT Dr Georgi Stranski EAD /ID# 237830

    Pleven, Bulgaria

  • Multiprofile Hospital for Active Treatment ( UMHAT) Sveti Georgi EAD Plovdiv /ID# 235487

    Plovdiv, Bulgaria

  • UMHAT Sveti Georgi /ID# 237026

    Plovdiv, Bulgaria

  • UMHAT Kanev /ID# 237809

    Rousse, Bulgaria

  • Medical center 1 Sevlievo /ID# 237470

    Sevlievo, Bulgaria

  • MHATEM N.I.Pirogov Septic Surgery Clinic /ID# 235541

    Sofia, Bulgaria

  • SHAT Hematologic Diseases /ID# 237915

    Sofia, Bulgaria

  • University Multiprofile Hospital for Active Treatment Prof. Dr. Stoyan Kirkovich /ID# 235543

    Stara Zagora, Bulgaria

  • Hospital de Ninos Dr. Roberto del Rio /ID# 235568

    Independencia, Chile

  • Hospital El Carmen de Maipú /ID# 235570

    Santiago, Chile

  • Hospital Universitario San Vic /ID# 238117

    Medellín, Colombia

  • Fundacion Cardioinfantil /Id# 238041

    Bogota, Cundinamarca, Colombia

  • Unidad De Investigacion Clinica Universidad De La Sabana /ID# 235566

    Chía, Cundinamarca, Colombia

  • LTD Unimedi Kakheti Batumi Maternal and Child Healthcare Center /ID# 235643

    Batumi, Georgia

  • LEPL Tbilisi State Medical University Givi Zhvania Academic Clinic of Pediatry /ID# 235645

    Tbilisi, Georgia

  • LTD M. Iashvili Children's Central Hospital /ID# 235639

    Tbilisi, Georgia

Showing 40 of 84 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.